nach oben

Erschienen in:

12.09.2023 | Valvular Heart Disease (TL Kiefer, Section Editor)

Update on Transcatheter Treatment of Mitral and Tricuspid Valve Regurgitation

verfasst von: David Meier, Mariama Akodad, Georgios Tzimas, Olivier Muller, Anson Cheung, David A. Wood, Philipp Blanke, Janarthanan Sathananthan, Fabien Praz, Robert H. Boone, John G. Webb

Erschienen in: Current Cardiology Reports | Ausgabe 10/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Mitral and tricuspid regurgitation represents a clinical challenge. They are associated with a poor prognosis, and many patients are not eligible for conventional surgery. Transcatheter therapies have been the focus of numerous studies and devices over the past decade. Here, we provide a summary of current options for transcatheter treatment of these 2 entities.

Recent Findings

Recent studies have demonstrated the benefits of edge-to-edge repair for increasing numbers of patients. Encouraging early results with transcatheter valve replacement are also becoming available.

Summary

To date, transcatheter edge-to-edge repair is currently the first-line transcatheter treatment for both mitral and tricuspid regurgitation for many patients who are not candidates for surgery. A number of transcatheter replacement devices are under development and clinical investigation but, for the most part, their current use is limited to compassionate cases or clinical trials.

Tung M, Nah G, Tang J, Marcus G, Delling FN. Valvular disease burden in the modern era of percutaneous and surgical interventions: the UK Biobank. Open Heart 2022;9.

Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143:e35–71.PubMed

Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561–632.PubMedCrossRef

Mack M, Carroll JD, Thourani V, et al. Transcatheter mitral valve therapy in the United States: a report from the STS-ACC TVT Registry. J Am Coll Cardiol. 2021;78:2326–53.PubMedCrossRef

Stone GW, Abraham WT, Lindenfeld J, et al. Five-year follow-up after transcatheter repair of secondary mitral regurgitation. N Engl J Med. 2023;388:2037–48.PubMedCrossRef

Scotti A, Munafo A, Adamo M, et al. Transcatheter edge-to-edge repair in COAPT-ineligible patients: incidence and predictors of 2-year good outcome. Can J Cardiol. 2022;38:320–9.PubMedCrossRef

Hausleiter J, Stocker TJ, Adamo M, Karam N, Swaans MJ, Praz F. Mitral valve transcatheter edge-to-edge repair. EuroIntervention. 2023;18:957–76.PubMedCrossRef

D. Scott Lim HCH, Paul Grayburn, Konstantinos Koulogiannis, Gorav Ailawadi,, Mathew Williams VGN, Katherine H. Chau, Paul Sorajja, Robert L. Smith II,, Mayra Guerrero DD, Juan F. Granada, Michael J. Mack, Martin B. Leon,, Patrick McCarthy. Consensus document on non-suitability for transcatheter mitral valve repair by edge-to-edge therapy. STRUCTURAL HEART 2021;VOL. 5, NO. 3, 227–233.

Buzzatti N, Van Hemelrijck M, Denti P, et al. Transcatheter or surgical repair for degenerative mitral regurgitation in elderly patients: a propensity-weighted analysis. J Thorac Cardiovasc Surg. 2019;158(86–94): e1.

10.

Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011;364:1395–406.PubMedCrossRef

11.

Stone GW, Weissman NJ, Mack MJ, Investigators C. Transcatheter mitral-valve repair in patients with heart failure. Reply N Engl J Med. 2019;380:1980–1.PubMed

12.

Chhatriwalla AK, Vemulapalli S, Holmes DR Jr, et al. Institutional experience with transcatheter mitral valve repair and clinical outcomes: insights from the TVT Registry. JACC Cardiovasc Interv. 2019;12:1342–52.PubMedCrossRef

13.

•• von Bardeleben RS, Rogers JH, Mahoney P, et al. Real-world outcomes of fourth-generation mitral transcatheter repair: 30-day results from EXPAND G4. JACC Cardiovasc Interv. 2023;16:1463–73. Large all-comers registry of contemporary outcomes of M-TEER using fourth generation MitraClip.CrossRef

14.

Kar S, von Bardeleben RS, Rottbauer W, et al. Contemporary outcomes following transcatheter edge-to-edge repair: 1-year results from the EXPAND Study. JACC Cardiovasc Interv. 2023;16:589–602.PubMedCrossRef

15.

Szerlip M, Spargias KS, Makkar R, et al. 2-year outcomes for transcatheter repair in patients with mitral regurgitation from the CLASP Study. JACC Cardiovasc Interv. 2021;14:1538–48.PubMedCrossRef

16.

Mauri V, Sugiura A, Spieker M, et al. Early outcomes of 2 mitral valve transcatheter leaflet approximation devices: a propensity score-matched multicenter comparison. JACC Cardiovasc Interv. 2022;15:2541–51.PubMedCrossRef

17.

Lim DS, Smith RL, Gillam LD, et al. Randomized comparison of transcatheter edge-to-edge repair for degenerative mitral regurgitation in prohibitive surgical risk patients. JACC Cardiovasc Interv. 2022;15:2523–36.PubMedCrossRef

18.

Geis NA, Schlegel P, Heckmann MB, Katus HA, Frey N, Crespo Lopez P, Raake PWJ. One-year results following PASCAL-based or MitraClip-based mitral valve transcatheter edge-to-edge repair. ESC Heart Fail. 2022;9:853–65.PubMedPubMedCentralCrossRef

19.

Luedike P, Riebisch M, Schindhelm F, et al. Impact of mitral valve repair technologies on predictability of post-delivery residual mitral regurgitation. JACC Cardiovasc Interv. 2021;14:2638–40.PubMedCrossRef

20.

Sorajja P, Vemulapalli S, Feldman T, et al. Outcomes with transcatheter mitral valve repair in the United States: an STS/ACC TVT Registry Report. J Am Coll Cardiol. 2017;70:2315–27.PubMedCrossRef

21.

Rogers JH, Asch F, Sorajja P, et al. Expanding the spectrum of TEER suitability: evidence from the EXPAND G4 post approval study. JACC Cardiovasc Interv. 2023;16:1474–85.PubMedCrossRef

22.

Hausleiter J, Lim DS, Gillam LD, et al. Transcatheter edge-to-edge repair in patients with anatomically complex degenerative mitral regurgitation. J Am Coll Cardiol. 2023;81:431–42.PubMedCrossRef

23.

Liu X, Chen M, Han Y, et al. First-in-human study of the novel transcatheter mitral valve repair system for mitral regurgitation. JACC Asia. 2022;2:390–4.PubMedPubMedCentralCrossRef

24.

Khatib D, Neuburger PJ, Pan S, Rong LQ. Transcatheter mitral valve interventions for mitral regurgitation: a review of mitral annuloplasty, valve replacement, and chordal repair devices. J Cardiothorac Vasc Anesth. 2022;36:3887–903.PubMedCrossRef

25.

Chen M, Sun L. What is the next generation of transcatheter mitral valve repair devices? Front Cardiovasc Med. 2021;8: 641691.PubMedPubMedCentralCrossRef

26.

Anker SD, Starling RC, Khan MS, et al. Percutaneous mitral valve annuloplasty in patients with secondary mitral regurgitation and severe left ventricular enlargement. JACC Heart Fail. 2021;9:453–62.PubMedCrossRef

27.

Gerosa G, Nadali M, Longinotti L, et al. Transapical off-pump echo-guided mitral valve repair with neochordae implantation mid-term outcomes. Ann Cardiothorac Surg. 2021;10:131–40.PubMedPubMedCentralCrossRef

28.

Regueiro A, Ye J, Fam N, et al. 2-year outcomes after transcatheter mitral valve replacement. JACC Cardiovasc Interv. 2017;10:1671–8.PubMedCrossRef

29.

Cheung A. Early experience of TIARA transcatheter mitral valve replacement system. Ann Cardiothorac Surg. 2018;7:787–91.PubMedPubMedCentralCrossRef

30.

Cohen DJ, Ludwig S, Piazza N. Transcatheter mitral valve replacement will remain a niche therapy: pros and cons. EuroIntervention. 2023;18:1222–5.PubMed

31.

Alperi A, Granada JF, Bernier M, Dagenais F, Rodes-Cabau J. Current status and future prospects of transcatheter mitral valve replacement: JACC state-of-the-art review. J Am Coll Cardiol. 2021;77:3058–78.PubMedCrossRef

32.

•• Ludwig S, Perrin N, Coisne A et al. Clinical outcomes of transcatheter mitral valve replacement: two-year results of the CHOICE-MI Registry. EuroIntervention 2023. Largest TMVR registry to date, illustrating clinical benefits but also challenges of TMVR.

33.

Alperi A, Avanzas P, Leon V, et al. Current status of transcatheter mitral valve replacement: systematic review and meta-analysis. Front Cardiovasc Med. 2023;10:1130212.PubMedPubMedCentralCrossRef

34.

Wild MG, Kreidel F, Hell MM, et al. Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a real-world multicentre experience. Eur J Heart Fail. 2022;24:899–907.PubMedCrossRef

35.

Muller DWM, Sorajja P, Duncan A, et al. 2-year outcomes of transcatheter mitral valve replacement in patients with severe symptomatic mitral regurgitation. J Am Coll Cardiol. 2021;78:1847–59.PubMedCrossRef

36.

Rodes-Cabau J, Regueiro A, Mack MJ. Transcatheter mitral valve replacement: a need for better patient selection. J Am Coll Cardiol. 2021;78:1860–2.PubMedCrossRef

37.

Ludwig S, Conradi L, Cohen DJ, et al. Transcatheter mitral valve replacement versus medical therapy for secondary mitral regurgitation: a propensity score-matched comparison. Circ Cardiovasc Interv. 2023;16: e013045.PubMedCrossRef

38.

Bapat V, Rajagopal V, Meduri C, et al. Early experience with new transcatheter mitral valve replacement. J Am Coll Cardiol. 2018;71:12–21.PubMedCrossRef

39.

Makkar R ONW, Whisenant B, et al. Updated 30-Day Outcomes for the U.S. Early feasibility study of the SAPIEN M3 transcatheter mitral valve replacement system. J Am Coll Cardiol 2019;Sep 1;74(13):B8.

40.

Goel SS, Zuck V, Christy J, Nallamothu N, Jagtap P, Gao J, Goswami NJ. Transcatheter mitral valve therapy with novel supra-annular AltaValve: first experience in the United States. JACC Case Rep. 2019;1:761–4.PubMedPubMedCentralCrossRef

41.

Webb J, Hensey M, Fam N, et al. Transcatheter mitral valve replacement with the transseptal EVOQUE system. JACC Cardiovasc Interv. 2020;13:2418–26.PubMedCrossRef

42.

Alperi A, Dagenais F, Del Val D, et al. Early experience with a novel transfemoral mitral valve implantation system in complex degenerative mitral regurgitation. JACC Cardiovasc Interv. 2020;13:2427–37.PubMedCrossRef

43.

Niikura H, Gossl M, Kshettry V, et al. Causes and clinical outcomes of patients who are ineligible for transcatheter mitral valve replacement. JACC Cardiovasc Interv. 2019;12:196–204.PubMedCrossRef

44.

Ben Ali W, Ludwig S, Duncan A, et al. Characteristics and outcomes of patients screened for transcatheter mitral valve implantation: 1-year results from the CHOICE-MI registry. Eur J Heart Fail. 2022;24:887–98.PubMedCrossRef

45.

Coisne A, Pontana F, Tchetche D, et al. Transcatheter mitral valve replacement: factors associated with screening success and failure. EuroIntervention. 2019;15:e983–9.PubMedCrossRef

46.

Eleid MF, Collins JD, Mahoney P, et al. Emerging approaches to management of left ventricular outflow obstruction risk in transcatheter mitral valve replacement. JACC Cardiovasc Interv. 2023;16:885–95.PubMedCrossRef

47.

Ludwig S, Kalbacher D, Ali WB, et al. Transcatheter mitral valve replacement or repair for secondary mitral regurgitation: a propensity score-matched analysis. Eur J Heart Fail. 2023;25:399–410.PubMedCrossRef

48.

Al-Tawil M, Butt S, Reap S, et al. Transseptal vs transapical transcatheter mitral valve-in-valve and valve-in-ring implantation: a systematic review and meta-analysis. Curr Probl Cardiol. 2023;48: 101684.PubMedCrossRef

49.

Guerrero M, Pursnani A, Narang A, et al. Prospective evaluation of transseptal TMVR for failed surgical bioprostheses: MITRAL trial valve-in-valve arm 1-year outcomes. JACC Cardiovasc Interv. 2021;14:859–72.PubMedCrossRef

50.

Whisenant B, Kapadia SR, Eleid MF, et al. One-year outcomes of mitral valve-in-valve using the SAPIEN 3 transcatheter heart valve. JAMA Cardiol. 2020;5:1245–52.PubMedPubMedCentralCrossRef

51.

Eleid MF, Wang DD, Pursnani A, et al. 2-year outcomes of transcatheter mitral valve replacement in patients with annular calcification, rings, and bioprostheses. J Am Coll Cardiol. 2022;80:2171–83.PubMedCrossRef

52.

Simonato M, Whisenant B, Ribeiro HB, et al. Transcatheter mitral valve replacement after surgical repair or replacement: comprehensive midterm evaluation of valve-in-valve and valve-in-ring implantation from the VIVID Registry. Circulation. 2021;143:104–16.PubMedCrossRef

53.

Enriquez-Sarano M, Messika-Zeitoun D, Topilsky Y, Tribouilloy C, Benfari G, Michelena H. Tricuspid regurgitation is a public health crisis. Prog Cardiovasc Dis. 2019;62:447–51.PubMedCrossRef

54.

Scotti A, Sturla M, Granada JF, et al. Outcomes of isolated tricuspid valve replacement: a systematic review and meta-analysis of 5,316 patients from 35 studies. EuroIntervention. 2022;18:840–51.PubMedCrossRef

55.

Dreyfus J, Flagiello M, Bazire B, et al. Isolated tricuspid valve surgery: impact of aetiology and clinical presentation on outcomes. Eur Heart J. 2020;41:4304–17.PubMedCrossRef

56.

Groger M, Friedl S, Ouerghemmi D et al. TRI-SCORE is superior to EuroSCORE II and STS-Score in mortality prediction following transcatheter edge-to-edge tricuspid valve repair. Clin Res Cardiol 2023.

57.

Vogelhuber J, Tanaka T, Sugiura A et al. Association of TRI-SCORE with clinical outcomes after transcatheter tricuspid valve repair. JACC Cardiovasc Interv 2023.

58.

Lurz P, Stephan von Bardeleben R, Weber M et al. Transcatheter edge-to-edge repair for treatment of tricuspid regurgitation. J Am Coll Cardiol 2021;77:229–239.

59.

Lurz P, Besler C, Schmitz T et al. Short-term outcomes of tricuspid edge-to-edge repair in clinical practice. J Am Coll Cardiol 2023.

60.

•• Sorajja P, Whisenant B, Hamid N, et al. Transcatheter repair for patients with tricuspid regurgitation. N Engl J Med. 2023;388:1833–42. Pivotal randomized trial on TEER versus medical management for severe TR.PubMedCrossRef

61.

Fam NP, Ho EC, Zahrani M, Samargandy S, Connelly KA. Transcatheter tricuspid valve repair with the PASCAL system. JACC Cardiovasc Interv. 2018;11:407–8.PubMedCrossRef

62.

Fam NP, Braun D, von Bardeleben RS, et al. Compassionate use of the PASCAL transcatheter valve repair system for severe tricuspid regurgitation: a multicenter, observational, first-in-human experience. JACC Cardiovasc Interv. 2019;12:2488–95.PubMedCrossRef

63.

Kodali S, Hahn RT, Eleid MF, et al. Feasibility study of the transcatheter valve repair system for severe tricuspid regurgitation. J Am Coll Cardiol. 2021;77:345–56.PubMedCrossRef

64.

Nickenig G, Weber M, Schuler R, et al. Tricuspid valve repair with the Cardioband system: two-year outcomes of the multicentre, prospective TRI-REPAIR study. EuroIntervention. 2021;16:e1264–71.PubMedPubMedCentralCrossRef

65.

Nickenig G, Friedrichs KP, Baldus S, et al. Thirty-day outcomes of the Cardioband tricuspid system for patients with symptomatic functional tricuspid regurgitation: the TriBAND study. EuroIntervention. 2021;17:809–17.PubMedPubMedCentralCrossRef

66.

Stolz L, Weckbach LT, Hahn RT, et al. 2-year outcomes following transcatheter tricuspid valve replacement using the EVOQUE system. J Am Coll Cardiol. 2023;81:2374–6.PubMedCrossRef

67.

Webb JG, Chuang AM, Meier D, et al. Transcatheter tricuspid valve replacement with the EVOQUE system: 1-year outcomes of a multicenter, first-in-human experience. JACC Cardiovasc Interv. 2022;15:481–91.PubMedCrossRef

68.

Kodali S, Hahn RT, George I, et al. Transfemoral tricuspid valve replacement in patients with tricuspid regurgitation: TRISCEND study 30-day results. JACC Cardiovasc Interv. 2022;15:471–80.PubMedCrossRef

69.

Teiger E, Nejjari M, Lim P, et al. First-in-human implantation of the Topaz transcatheter tricuspid valve replacement system. EuroIntervention. 2022;18:862–4.PubMedCrossRef

70.

Lu FL, An Z, Ma Y, et al. Transcatheter tricuspid valve replacement in patients with severe tricuspid regurgitation. Heart. 2021;107:1664–70.PubMedCrossRef

71.

Zhang Y, Lu F, Li W et al. A first-in-human study of transjugular transcatheter tricuspid valve replacement with the LuX-Valve Plus system. EuroIntervention 2022.

72.

Estevez-Loureiro R, Sanchez-Recalde A, Amat-Santos IJ, et al. 6-month outcomes of the tricvalve system in patients with tricuspid regurgitation: the TRICUS EURO study. JACC Cardiovasc Interv. 2022;15:1366–77.PubMedCrossRef

73.

Amat-Santos IJ, Estevez-Loureiro R, Sanchez-Recalde A et al. Right heart remodelling after bicaval TricValve implantation in patients with severe tricuspid regurgitation. EuroIntervention 2023.

74.

Wild MG, Lubos E, Cruz-Gonzalez I, et al. Early clinical experience with the TRICENTO bicaval valved stent for treatment of symptomatic severe tricuspid regurgitation: a multicenter registry. Circ Cardiovasc Interv. 2022;15: e011302.PubMedCrossRef

75.

Guenther T, Noebauer C, Mazzitelli D, Busch R, Tassani-Prell P, Lange R. Tricuspid valve surgery: a thirty-year assessment of early and late outcome. Eur J Cardiothorac Surg 2008;34:402–9; discussion 409.

76.

Dreyfus J, Bohbot Y, Coisne A, et al. Predictive value of the TRI-SCORE for in-hospital mortality after redo isolated tricuspid valve surgery. Heart. 2023;109:951–8.PubMedCrossRef

77.

McElhinney DB, Aboulhosn JA, Dvir D, et al. Mid-term valve-related outcomes after transcatheter tricuspid valve-in-valve or valve-in-ring replacement. J Am Coll Cardiol. 2019;73:148–57.PubMedCrossRef

78.

Anderson JH, McElhinney DB, Aboulhosn J, et al. Management and outcomes of transvenous pacing leads in patients undergoing transcatheter tricuspid valve replacement. JACC Cardiovasc Interv. 2020;13:2012–20.PubMedCrossRef

Titel: Update on Transcatheter Treatment of Mitral and Tricuspid Valve Regurgitation
verfasst von: David Meier
Mariama Akodad
Georgios Tzimas
Olivier Muller
Anson Cheung
David A. Wood
Philipp Blanke
Janarthanan Sathananthan
Fabien Praz
Robert H. Boone
John G. Webb
Publikationsdatum: 12.09.2023
Verlag: Springer US
Erschienen in: Current Cardiology Reports / Ausgabe 10/2023
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-023-01954-y

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Update on Transcatheter Treatment of Mitral and Tricuspid Valve Regurgitation